BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 26012464)

  • 21. Novel oral anticoagulants in secondary prevention of stroke.
    Diener HC; Easton JD; Hankey GJ; Hart RG
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):131-9. PubMed ID: 23953901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concerns about studies investigating new anticoagulant drugs for stroke prevention in atrial fibrillation.
    Stöllberger C; Finsterer J
    J Neurol; 2012 Jan; 259(1):168-9. PubMed ID: 22124666
    [No Abstract]   [Full Text] [Related]  

  • 23. New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation.
    Tripodi A; Palareti G
    J Intern Med; 2012 Jun; 271(6):554-65. PubMed ID: 22443239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
    Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indirect comparison studies--are they useful? Insights from the novel oral anticoagulants for stroke prevention in atrial fibrillation.
    Skjøth F; Larsen TB; Rasmussen LH
    Thromb Haemost; 2012 Sep; 108(3):405-6. PubMed ID: 22782445
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of atrial fibrillation.
    Med Lett Drugs Ther; 2014 Jul; 56(1446):53-8. PubMed ID: 25046325
    [No Abstract]   [Full Text] [Related]  

  • 27. {blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF.
    Drug Ther Bull; 2014 Jan; 52(1):6-9. PubMed ID: 24401533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
    Douketis J; Bell AD; Eikelboom J; Liew A
    Can Fam Physician; 2014 Nov; 60(11):989-95. PubMed ID: 25392438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response.
    Douketis J; Eikelboom J; Liew A; Bell AD
    Can Fam Physician; 2015 Jan; 61(1):24-5. PubMed ID: 25609517
    [No Abstract]   [Full Text] [Related]  

  • 32. Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.
    Douketis J; Bell AD; Eikelboom J; Liew A
    Can Fam Physician; 2014 Nov; 60(11):997-1001. PubMed ID: 25392439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outpatient management of oral anticoagulation in atrial fibrillation.
    Manning JA
    Crit Care Nurs Clin North Am; 2013 Dec; 25(4):481-7, vi. PubMed ID: 24267284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The role of internal medicine in preventing stroke in atrial fibrillation].
    Hernández M; Suárez C
    Med Clin (Barc); 2012 Oct; 139 Suppl 2():36-40. PubMed ID: 23498071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis.
    Tran H; Joseph J; Young L; McRae S; Curnow J; Nandurkar H; Wood P; McLintock C
    Intern Med J; 2014 Jun; 44(6):525-36. PubMed ID: 24946813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Well-managed warfarin is superior to NOACs.
    Trusler M
    Can Fam Physician; 2015 Jan; 61(1):23-4. PubMed ID: 25609516
    [No Abstract]   [Full Text] [Related]  

  • 38. New antithrombotic drugs and European approval processes.
    Marijon E; Fauchier L; Le Heuzey JY
    Lancet; 2011 Aug; 378(9792):662-3. PubMed ID: 21856473
    [No Abstract]   [Full Text] [Related]  

  • 39. Head-to-head or indirect comparisons of the novel oral anticoagulants in atrial fibrillation: what's next?
    Harenberg J; Marx S; Wehling M
    Thromb Haemost; 2012 Sep; 108(3):407-9. PubMed ID: 22837027
    [No Abstract]   [Full Text] [Related]  

  • 40. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Dumont B; Faille D; Ajzenberg N
    Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.